Skip to content
CancerIndex

Publication

Surface-engineered milk-derived extracellular vesicles enable oral miRNA therapy against immunosuppressive pancreatic cancer.

Youngri Ryu, Hochung Jang, Eun Hye Kim, Junha Lee, Byeongmin Park, Yewon Cho, Wonjun Kim, Hong-Yeol Yoon, Sun Hwa Kim, Dae-Hyuk Kweon, Man Kyu Shim, Yoosoo Yang

Materials today. BioOct 1, 2026PMID 42701371doi:10.1016/j.mtbio.2026.103600 PMC13545355Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 19, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260919-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Pancreatic ductal adenocarcinoma (PDAC) shows limited responsiveness to conventional therapies due to an immunosuppressive tumor microenvironment (TME) characterized by programmed death-ligand 1 (PD-L1)-mediated immune escape and oncogenic microRNA-21 (miR-21) signaling. Despite the potential of…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.